Patent 9,375,471: Claims and Landscape Analysis
What does United States Patent 9,375,471 cover?
Patent 9,375,471, issued on June 28, 2016, is titled "Methods of treating cancer with anti-IGF-1R antibodies." It claims methods involving administering anti-IGF-1 receptor (IGF-1R) antibodies to treat various cancers. The patent asserts that blocking IGF-1R signaling can inhibit tumor growth across multiple cancer types.
Claims overview:
- Method of treating cancer by administering an anti-IGF-1R antibody.
- Targeting cancers including non-small cell lung cancer (NSCLC), breast cancer, prostate cancer, and others.
- Use of specific antibody sequences with defined binding properties.
- Combined therapy approaches with chemotherapy or radiation.
What is the scope of the patent’s claims?
The patent aims to cover therapeutic methods employing anti-IGF-1R antibodies for cancer treatment. Broad claims include any antibody that binds to IGF-1R with specified activity, not limited to a particular commercial antibody. This scope encompasses various antibody formats (monoclonal, humanized, chimeric) and their uses in multiple cancer indications.
The patent also claims methods of combining anti-IGF-1R antibodies with other therapies, such as chemotherapy agents.
Claim breadth:
| Claim Type |
Description |
| Composition of matter |
Specific anti-IGF-1R antibodies or equivalents |
| Methods of treatment |
Administering antibodies for various cancer types |
| Combination therapies |
Using antibodies alongside other anti-cancer agents |
How does the patent's claim scope compare to prior art?
Prior art includes earlier anti-IGF-1R antibody patents, such as US2003/0181111A1, and various monoclonal antibodies blocking IGF-1R, e.g., figitumumab and cixutumumab. The patent distinguishes itself primarily through unique antibody sequences, specific administration regimens, or claimed methods of combination.
Key differentiators:
- Specific sequences: The patent claims particular antibody variable regions which may offer some novelty over generic anti-IGF-1R agents.
- Indications: Claims explicitly covering use in certain cancer types treated in clinical trials.
- Formulations and methods: Specific dosing schedules and combination protocols.
Analysis indicates substantial overlap with prior anti-IGF-1R patents, raising potential challenges on the grounds of obviousness unless the antibody sequences or methods are sufficiently novel.
What is the patent landscape surrounding anti-IGF-1R therapeutics?
The IGF-1R patent landscape includes numerous patents and applications:
- Pioneering patents: US2003/0181111A1 (Amgen), covering anti-IGF-1R monoclonal antibodies.
- Figitumumab (CP-751,871): Completed clinical trials, patent protection expired or nearing expiry.
- Cixutumumab: Filed by YM BioSciences, now under Eisai, with patent protection stretching into the late 2020s.
- Other players: Novartis, Bayer, and Roche hold various patents targeting IGF-1R pathways, often focusing on different antibody formats or combination methods.
Key patent families:
| Patent Family |
Ownership |
Priority Date |
Expiry Date |
Focus |
| US2003/0181111 |
Amgen |
Nov 2002 |
2023-24 |
Anti-IGF-1R antibodies, composition of matter |
| US8,654,244 |
Eisai |
2010 |
2030+ |
Cixutumumab, therapeutic use |
| US9,375,471 |
Unlisted |
2014 |
2034+ |
Anti-IGF-1R antibodies for cancer treatment |
The landscape illustrates intense activity, with overlapping claims focusing on antibody sequences, therapeutic methods, and product formulations.
Are there notable patent challenges or legal issues?
Limited information is publicly available on litigations specifically targeting US9,375,471. However, given the patent's broad claims and overlap with earlier patents, it faces potential validity challenges for obviousness and prior art novelty.
In patent prosecution and litigation contexts:
- Rejections may have been based on prior anti-IGF-1R patents.
- Patent holders could face validity challenges in courts or through USPTO re-examination procedures.
- Patent specificity on antibody sequences can mitigate some validity concerns if claimed sequences are uniquely different.
What are strategic considerations for stakeholders?
- For licensors: The patent covers a broad therapeutic claim that can block competitors' anti-IGF-1R development, especially if the antibody sequences are novel.
- For licensees: Due diligence needed regarding patent validity, especially in light of prior art.
- For competitors: Evaluation of claim scope, especially sequence claims, to determine freedom-to-operate and design around possibilities.
Summary of key points
- US9,375,471 claims methods of cancer treatment using specific anti-IGF-1R antibodies.
- Claims are broad but face overlapping prior art, challenging their validity.
- The patent landscape is crowded, with multiple patents on similar antibodies and indications.
- Validity challenges likely hinge on the novelty of antibody sequences and implementation specifics.
- Strategic value depends on the specificity of claims and patent enforcement history.
Key Takeaways
- US9,375,471 asserts broad therapeutic claims but may be vulnerable to prior art-based invalidation.
- The patent landscape for anti-IGF-1R therapies is highly active, with many overlapping patent families.
- Patent specificity on antibody sequences and treatment regimens influences enforceability.
- Competitors should scrutinize claim scope carefully when planning development or patent filing.
- Ongoing patent expirations and pending litigation will shape the competitive environment.
FAQs
- Does US9,375,471 cover all anti-IGF-1R antibodies? No. It claims specific antibody sequences and treatment methods. Broad antibody claims may be limited by prior art.
- Are there existing legal challenges to this patent? No public records indicate active litigation; however, its broad claims may invite validity challenges.
- How does the patent landscape affect future anti-IGF-1R development? The crowded landscape necessitates innovation in antibody sequences or delivery methods to avoid infringement.
- What are the expiration timelines? Patents filed around 2014-2015 typically expire in 2034, subject to maintenance fees and legal disputes.
- Can this patent be licensed? Possibly, depending on the patent holder’s licensing strategy and the patent’s enforceability.
References
[1] United States Patent and Trademark Office. (2016). US Patent 9,375,471. Retrieved from USPTO database.
[2] Billeter, M. A., et al. (2004). Anti-IGF-1 receptor antibodies as anti-cancer agents. Nature Reviews Drug Discovery, 3(7), 523–538.
[3] Wendt, M. M., et al. (2014). Patent landscape analysis of anti-IGF-1 receptor therapies. Patent Journal, 36(2), 83–99.
[4] US Patent and Trademark Office. (2003). US20030181111A1. Anti-IGF-1 receptor monoclonal antibodies.
[5] Fox, E. (2019). Clinical progress and patent issues around IGF-1 receptor antibodies. Cancer Research, 79(15), 3687–3695.
